磁共振图像引导自适应立体定向体部放疗治疗前列腺癌:疗效与毒性的初步结果
本研究纳入50例接受超低分割立体定向体部放疗的前列腺癌患者,采用MRI引导自适应放疗、每日计划调整,方案为36.25 Gy分5次、单次7.25 Gy。中位随访10个月,急性1级和2级泌尿生殖毒性分别为28%和36%,无≥2级胃肠道毒性;作者认为该方案急性和晚期毒性可接受。
要点
- MRI引导自适应立体定向体部放疗采用无标记软组织可视化和在线自适应计划。
- 超低分割方案为36.25 Gy分5次,单次7.25 Gy,每日进行计划调整。
- 急性1级和2级泌尿生殖毒性分别为28%和36%,无≥2级胃肠道毒性。
核心结论
- MRI引导自适应放疗是实施立体定向体部放疗的新方法,具备无标记软组织可视化、在线自适应计划和实时追踪。
- 作者认为超低分割方案急性和晚期毒性均较低、可接受。
- 因随访时间短,本队列前列腺特异性抗原最低值尚未达到。
研究设计与样本
- 研究为初步结果报告,纳入50例接受超低分割放疗的前列腺癌患者。
- 治疗采用调强放疗(step and shoot技术)联合MRI引导自适应放疗进行每日计划调整。
- 立体定向体部放疗方案为36.25 Gy分5次,单次7.25 Gy。
- 记录工作流程各步骤时间,随访急性和晚期毒性及前列腺特异性抗原反应。
诊断标准与关键数值
- 中位随访10个月(范围3至29个月),中位年龄73.5岁(范围50至84岁)。
- 急性泌尿生殖毒性1级和2级分别为28%和36%。
- 急性胃肠道毒性仅6%为1级,无≥2级胃肠道毒性。
- 晚期泌尿生殖毒性1级24%、2级2%;晚期胃肠道毒性2级6%。
临床应用与阅片要点
- MRI引导自适应放疗可在无标记条件下实现软组织可视化和在线自适应计划,并支持实时追踪。
- 超低分割立体定向体部放疗的急性毒性以1至2级泌尿生殖毒性为主,胃肠道毒性较低。
局限性
- 本研究为初步结果,随访时间短,中位随访10个月(范围3至29个月)。
- 因随访时间短,本队列前列腺特异性抗原最低值尚未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response.
METHODS: 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response.
RESULTS: The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort.
CONCLUSION: In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile.
ADVANCES IN KNOWLEDGE: MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.
引用
- Ugurluer G, Atalar B, Zoto Mustafayev T, et al. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity. Br J Radiol. 2020. PMID: 33095670. doi:10.1259/bjr.20200696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。